1-4 of 4
Gene M. Williams
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan-Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3205–3209.
https://doi.org/10.1158/1078-0432.CCR-18-3749
Published: 03 June 2019
View article titled, FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Open the PDF for FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation in another window
Includes: Supplementary data
Journal Articles

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

Shakun M. Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, W. David McGuinn, Jr., S. Leigh Verbois, Anshu Marathe, Gene M. Williams, Julie Bullock, Christoffer Tornoe, Sue Ching Lin, Terrance Ocheltree, Milinda Vialpando, Alice Kacuba, Robert Justice, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (20): 4921–4927.
https://doi.org/10.1158/1078-0432.CCR-10-1214
Published: 13 October 2010
View article titled, Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary
Open the PDF for Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary in another window
Journal Articles

Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

John R. Johnson, Martin Cohen, Rajeshwari Sridhara, Yeh-Fong Chen, Gene M. Williams, John Duan, Jogarao Gobburu, Brian Booth, Kimberly Benson, John Leighton, Li Shan Hsieh, Nallalerumal Chidambaram, Paul Zimmerman, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6414–6421.
https://doi.org/10.1158/1078-0432.CCR-05-0790
Published: 15 September 2005
View article titled, Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen
Open the PDF for Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen in another window
Journal Articles

Fulvestrant in Postmenopausal Women with Advanced Breast Cancer

Peter F. Bross, Amy Baird, Gang Chen, Josephine M. Jee, Richard T. Lostritto, David E. Morse, Liliam A. Rosario, Gene M. Williams, Peiling Yang, Atiqur Rahman, Grant Williams, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (12): 4309–4317.
Published: 10 October 2003
View article titled, Fulvestrant in Postmenopausal Women with Advanced Breast Cancer
Open the PDF for Fulvestrant in Postmenopausal Women with Advanced Breast Cancer in another window